[{"address1": "1111 Dr. Frederik-Philips Boulevard", "address2": "Suite 420", "city": "Montreal", "state": "QC", "zip": "H4M 2X6", "country": "Canada", "phone": "514 336 0444", "website": "https://www.milestonepharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montr\u00e9al, Canada.", "fullTimeEmployees": 47, "maxAge": 86400, "priceHint": 4, "previousClose": 1.39, "open": 1.3999, "dayLow": 1.37, "dayHigh": 1.405, "regularMarketPreviousClose": 1.39, "regularMarketOpen": 1.3999, "regularMarketDayLow": 1.37, "regularMarketDayHigh": 1.405, "beta": 1.732, "forwardPE": -1.1311475, "volume": 44710, "regularMarketVolume": 44710, "averageVolume": 179524, "averageVolume10days": 93620, "averageDailyVolume10Day": 93620, "bid": 1.37, "ask": 1.4, "bidSize": 200, "askSize": 300, "marketCap": 73499488, "fiftyTwoWeekLow": 1.33, "fiftyTwoWeekHigh": 3.86, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.6103, "twoHundredDayAverage": 2.095765, "currency": "USD", "enterpriseValue": 54318940, "floatShares": 52742014, "sharesOutstanding": 53260500, "sharesShort": 455084, "sharesShortPriorMonth": 431410, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0085, "heldPercentInsiders": 0.00694, "heldPercentInstitutions": 0.59071, "shortRatio": 3.12, "shortPercentOfFloat": 0.0086, "impliedSharesOutstanding": 53260500, "bookValue": 0.603, "priceToBook": 2.2885573, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -55089000, "trailingEps": -1.25, "forwardEps": -1.22, "enterpriseToEbitda": -0.971, "52WeekChange": -0.54605263, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MIST", "underlyingSymbol": "MIST", "shortName": "Milestone Pharmaceuticals Inc.", "longName": "Milestone Pharmaceuticals Inc.", "firstTradeDateEpochUtc": 1557408600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fef8fa0a-f2b8-346f-8ec3-172c3e402265", "messageBoardId": "finmb_36171059", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.38, "targetHighPrice": 25.0, "targetLowPrice": 2.0, "targetMeanPrice": 10.25, "targetMedianPrice": 7.0, "recommendationMean": 2.2, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 89481000, "totalCashPerShare": 1.353, "ebitda": -55970000, "totalDebt": 52505000, "quickRatio": 22.088, "currentRatio": 22.752, "debtToEquity": 131.522, "returnOnAssets": -0.33847, "returnOnEquity": -1.1739, "freeCashflow": -28365624, "operatingCashflow": -41454000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]